Gilead expands lenacapavir licensing to once-yearly HIV prevention PrEP
Gilead says it expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as PrEP.
Gilead Sciences, Inc. (Nasdaq: GILD) said it has broadened the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreements cover 120 high-incidence…